Trial · NCT07880145
Effects of Respiratory Muscle Strength Training in Children With Asthma
NCT07880145, Not applicable, Not yet recruiting, Hasan Kalyoncu University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Respiratory Muscle Strength Training in Children With Asthma. Trials, record NCT07880145. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880145
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Respiratory Muscle Strength Training in Children With Asthma
- NCT number
- NCT07880145
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 32 participants, estimated
- Lead sponsor
- Hasan Kalyoncu University
- Conditions
- Asthma (Diagnosis)
- Interventions
- Exercise, Exercise
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Inspiratory Muscle Strength | Baseline and after the 8-week intervention | nspiratory muscle strength will be assessed by measuring maximal inspiratory pressure (MIP) using a respiratory pressure measurement device (COSMED Pony FX, COSMED Srl, Rome, Italy) in accordance with ATS/ERS recommendations. MIP will be recorded in cmH2O. Measurements will be performed before and after the 8-week intervention. |
| Primary | Pulmonary Function | Baseline and immediately after the 8-week intervention | Pulmonary function will be assessed using spirometry. Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and the FEV1/FVC ratio will be recorded. Peak expiratory flow (PEF) will also be measured using a peak flow meter. Measurements will be performed before and after the 8-week intervention. |
| Primary | Inspiratory Muscle Endurance | Baseline and after the 8-week intervention | Inspiratory muscle endurance will be assessed using an incremental threshold loading test with a POWERbreathe Classic Light Resistance device. The test will begin at 20% of the participant's maximal inspiratory pressure (MIP), and the load will be increased by 20% of MIP every 2 minutes up to 100% of MIP. The highest successfully completed pressure will be recorded in cmH2O. Measurements will be performed before and after the 8-week intervention. |
| Secondary | Heart Rate Variability | Baseline and immediately after the 8-week intervention | Heart rate variability will be assessed using a Polar H10 heart rate sensor (Polar Electro Oy, Kempele, Finland) with Kubios HRV Scientific software. Low-frequency (LF) and high-frequency (HF) components will be obtained, and the LF/HF ratio will be used to assess sympathovagal balance. |
| Secondary | Functional Exercise Capacity | Baseline and immediately after the 8-week intervention | Functional exercise capacity will be assessed using the 6-Minute Walk Test (6MWT) according to American Thoracic Society recommendations. Participants will walk along a 30-meter course for 6 minutes, and the total distance walked will be recorded in meters. The test will be performed twice with a 15-20-minute rest period between tests, and the greater walking distance will be used for analysis. |
| Secondary | Asthma Control | Baseline and immediately after the 8-week intervention | Asthma control will be assessed using the Turkish version of the Asthma Control Test (ACT). The ACT consists of 5 items assessing asthma symptoms, their effects on daily activities, and rescue medication use during the previous 4 weeks. The total score ranges from 5 to 25, with higher scores indicating better asthma control. Scores of 19 or lower indicate uncontrolled asthma, while scores of 20 or higher indicate controlled asthma. |
| Secondary | Asthma-Related Quality of Life | Baseline and immediately after the 8-week intervention | Asthma-related quality of life will be assessed using the Turkish version of the Pediatric Asthma Quality of Life Questionnaire (PAQLQ). The questionnaire consists of 23 items covering three domains: symptoms, activity limitations, and emotional function. Items are scored on a 7-point scale, with higher scores indicating better quality of life. |
| Secondary | Climate Change Anxiety | Baseline and immediately after the 8-week intervention | Climate change anxiety will be assessed using the Turkish version of the Climate Change Anxiety Scale. The scale consists of 13 items rated on a 5-point Likert scale ranging from 1 (Never) to 5 (Almost Always) and includes cognitive impairment and functional impairment subdomains. |
| Other | Sociodemographic Data | At the beginning of the study | Age, sex, Height, weight, BMI, Smoking status, economic status, drug treatments, duration of illness |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880145
GET https://conductscience.org/api/trials/v1/NCT07880145/registered